• ISSN 1674-8301
  • CN 32-1810/R
Volume 27 Issue 2
Mar.  2013
Turn off MathJax
Article Contents

Joshua Muli Mutiso, John Chege Macharia, Maria Ndunge Kiio, James Maina Ichagichu, Hitler Rikoi, Michael Muita Gicheru. Development of Leishmania vaccines: predicting the future from past and present experience[J]. The Journal of Biomedical Research, 2013, 27(2): 85-102. doi: 10.7555/JBR.27.20120064
Citation: Joshua Muli Mutiso, John Chege Macharia, Maria Ndunge Kiio, James Maina Ichagichu, Hitler Rikoi, Michael Muita Gicheru. Development of Leishmania vaccines: predicting the future from past and present experience[J]. The Journal of Biomedical Research, 2013, 27(2): 85-102. doi: 10.7555/JBR.27.20120064

Development of Leishmania vaccines: predicting the future from past and present experience

doi: 10.7555/JBR.27.20120064
  • Received Date: 2012-06-17
  • Publish Date: 2013-03-28
  • Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement and fatal systemic infection. Resistance to infection is associated with a T-helper-1 immune response that activates macrophages to kill the intracellular parasite in a nitric oxide-dependent manner. Conversely, disease progression is generally associated with a T-helper-2 response that activates humoral immunity. Current control is based on chemothera-peutic treatments which are expensive, toxic and associated with high relapse and resistance rates. Vaccination remains the best hope for control of all forms of the disease, and the development of a safe, effective and afford-able antileishmanial vaccine is a critical global public-health priority. Extensive evidence from studies in animal models indicates that solid protection can be achieved by immunization with defined subunit vaccines or live-at-tenuated strains of Leishmania. However, to date, no vaccine is available despite substantial efforts by many labo-ratories. Major impediments in Leishmania vaccine development include: lack of adequate funding from national and international agencies, problems related to the translation of data from animal models to human disease, and the transition from the laboratory to the field. Furthermore, a thorough understanding of protective immune re-sponses and generation and maintenance of the immunological memory, an important but least-studied aspect of antiparasitic vaccine development, during Leishmania infection is needed. This review focuses on the progress of the search for an effective vaccine against human and canine leishmaniasis.
  • 加载中
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(9513) PDF downloads(2989) Cited by()

Related
Proportional views

Development of Leishmania vaccines: predicting the future from past and present experience

doi: 10.7555/JBR.27.20120064

Abstract: Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement and fatal systemic infection. Resistance to infection is associated with a T-helper-1 immune response that activates macrophages to kill the intracellular parasite in a nitric oxide-dependent manner. Conversely, disease progression is generally associated with a T-helper-2 response that activates humoral immunity. Current control is based on chemothera-peutic treatments which are expensive, toxic and associated with high relapse and resistance rates. Vaccination remains the best hope for control of all forms of the disease, and the development of a safe, effective and afford-able antileishmanial vaccine is a critical global public-health priority. Extensive evidence from studies in animal models indicates that solid protection can be achieved by immunization with defined subunit vaccines or live-at-tenuated strains of Leishmania. However, to date, no vaccine is available despite substantial efforts by many labo-ratories. Major impediments in Leishmania vaccine development include: lack of adequate funding from national and international agencies, problems related to the translation of data from animal models to human disease, and the transition from the laboratory to the field. Furthermore, a thorough understanding of protective immune re-sponses and generation and maintenance of the immunological memory, an important but least-studied aspect of antiparasitic vaccine development, during Leishmania infection is needed. This review focuses on the progress of the search for an effective vaccine against human and canine leishmaniasis.

Joshua Muli Mutiso, John Chege Macharia, Maria Ndunge Kiio, James Maina Ichagichu, Hitler Rikoi, Michael Muita Gicheru. Development of Leishmania vaccines: predicting the future from past and present experience[J]. The Journal of Biomedical Research, 2013, 27(2): 85-102. doi: 10.7555/JBR.27.20120064
Citation: Joshua Muli Mutiso, John Chege Macharia, Maria Ndunge Kiio, James Maina Ichagichu, Hitler Rikoi, Michael Muita Gicheru. Development of Leishmania vaccines: predicting the future from past and present experience[J]. The Journal of Biomedical Research, 2013, 27(2): 85-102. doi: 10.7555/JBR.27.20120064

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return